Among the updates provided at the conference on Wednesday, Luminex discussed development and plans for the Verigene II system, and GenMark touted its ePlex test portfolio.
The firm is using collaborations to access the large, diverse cohorts it needs to support its goal of commercializing its SomaScan system as a clinical platform.
The companies will use Somalogic's SomaScan proteomic platform to measure levels of as many as 5,000 proteins in up to 40,000 of DeCode's patient samples.
The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.
The company said it plans to use the technology to derive clinical insights from the large-scale proteomic datasets generated by its SomaScan platform.
Using genotype and blood plasma protein information for thousands of healthy individuals, researchers documented variants influencing plasma protein levels.
The parties will use Somalogic's SomaScan platform to investigate the ability of protein measurements to affect patient care in a variety of clinical areas.
The company aims to sell its clinical products not as discrete tests but as sets of "insights" derived from patient proteomic data collected using the platform.
Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.
Wired reports that researchers have shown they could reprogram a DNA-based computer.
Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.
In Science this week: whole-genome sequencing of single sperm cells, and more.